Each tablet contains Clenbuterol HCI 0.02 mg.
MAVILEX TABLET is an oval, scored tablet, white in colour with markings
'DUO' and '861'.
ACTIONS AND MODE OR MECHANISMS OF ACTIONS
It is a broncholytic agent which acts through selective stimulation of the β2-receptors.
It differs from other β2-specific sympathomimetics by its
low dose, long biological half-life and rapid and complete absorption by
oral administration. It has no significant effects on β1-cardiac
Pharmacokinetics: Invasion half-life of Clenbuterol is 1 hour the
distribution corresponds to an open two compartment model with a
side-compartment. Elimination from plasma takes place in 2 phases, the
half-life of the a-phase being 1 hour and that of β-phase 34 hours.
Elimination is primarily renal (87% after 168 hours) 43% of Clenbuterol is
recovered unchanged in the urine. Dose intervals of 12 hours suffice to
maintain a plasma level. Five metabolites have been found in humans.
Prophylaxis and therapy of bronchospasm in bronchial asthma, acute and
chronic bronchitis associated with emphysema.
Thyrotoxicosis, idiopathic hypertrophic subvalvular aortic stenosis,
tachycardia, tachyarrhythmia. Known sensitivity to sympathomimetic amines.
SIDE EFFECTS/ADVERSE REACTIONS
Side effects rarely occur at the recommended doses. Some patients could
have, at the beginning of the treatment, tremor, nervousness, extrasystoles,
tachycardia, palpitations, vertigo, anxiety, headache and nausea. In these
cases the dose should be reduced.
Warnings: Although animal studies have shown no teratogenic effect,
Mavilex should not be given during the first three months of pregnancy.
Precautions: Care must be exercised when additional sympathomimetic
agents or IMAO drugs are administered. Mavilex should be used with caution
in patients with hypertension, coronary heart disease, hyperthyroidism and
diabetes. Caution should be used when treating patients with recent cardiac
Beta-blockers and Mavilex counteract the action of each other.
Clenbuterol is a direct-acting sympathomimetic agent with general properties
similar to those of Salbutamol. Theophylline may increase the risk of
hypokalaemia if given with high doses of Clenbuterol.
RECOMMENDED DOSAGE, DOSAGE SCHEDULE AND ROUTE OF ADMINISTRATION
The recommended total daily dose for adults and children over 12 years is
0.04 mg/day. In severe bronchospasm the dose may be increased to 0.08 mg/day
twice daily; as therapy continues, the dose may often be reduced to 0.02
mg/day. The recommended total daily dose for children is 0.0012 mg/kg body
weight, ranging from 0.0008 - 0.0015 mg Mavilex.
Tablet: Adults and children over 12 years: 0.02 mg twice
Twice daily doses morning and evening provide for constant blood levels. The
duration of treatment depends upon the symptoms and there is no objection to
SYMPTOMS AND TREATMENT FOR OVERDOSE AND ANTIDOTES
Overdosage may cause restlessness, anxiety, flushing, tachycardia,
pronounced tremor or rise in blood pressure. With tremor, enzymes specific
to muscle cells increase in the serum. A dose of 0.6 mg Clenbuterol was
tolerated without complications after a β-blocker was given
approximately 90 minutes after administration.
Treatment: Symptoms disappear immediately upon administration of β-blocker.
Treatment of overdosage should be cumulative at short interval, depending
upon the clinical picture. It should be noted that the action of Clenbuterol
can extend beyond that of the antagonist, so that it may be necessary to
repeat the administration of β-blocker.
In strips of 100's, 250's, 500's and 1000's.
In securitainers of 100, 250, 500 and 1000 tablets
Store below 25°C. Protect from light.
Shelf life 3 years. Keep out of reach of children.